---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: Human Neuroblastoma Cells Rapidly Enter Cell Cycle Arrest and Apoptosis Following Exposure to C-28 derivatives of the Synthetic Triterpenoid CDDO.
To: mesothelioma77@gmail.com
[1]Cell Cycle. 2008 Feb 7; 7(5):
Alabran JL, Cheuk A, Liby K, Sporn M, Khan J, Letterio J, Leskov KS
Synthetic triterpenoids, such as 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) and its derivatives, are an extremely potent class of new anti-cancer therapeutic agents, characterized by high antitumor potency and low toxicity to normal tissues. This report is the first to investigate the effects of C-28 derivatives of CDDO on 22 pediatric solid tumor cell lines, including neuroblastoma, rhabdomyosarcoma, osteosarcoma, and Ewing's sarcoma. We determined IC50s in the range of 5 - 170 nM for inhibition of colony formation and DNA synthesis, and 110 - 630 nM for metabolic cell death and decrease in cell number, using the C-28 CDDO analogs, CDDO methyl ester (CDDO-Me), CDDO imidazolide (CDDOIm), CDDO ethyl amide (CDDO-EA), CDDO trifluoroethyl amide (CDDO-TFEA), and CDDO diethylamide (CDDO-DE). After treatment of human neuroblastoma cells with CDDO-Me, cell cycle studies show depletion of the S-phase, while apoptosis studies show conformational activation and mitochondrial translocation of Bax protein, as well as activation of caspases -3 and -8. These data demonstrate the potential utility of CDDO analogs as promising novel therapeutic agents for high-risk pediatric solid tumors.
___
Source: http://www.hubmed.org/display.cgi?uids=18277094
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Feb 16, 2008 at 7:08 PM
Subject: Human Neuroblastoma Cells Rapidly Enter Cell Cycle Arrest and Apoptosis Following Exposure to C-28 derivatives of the Synthetic Triterpenoid CDDO.
To: mesothelioma77@gmail.com
[1]Cell Cycle. 2008 Feb 7; 7(5):
Alabran JL, Cheuk A, Liby K, Sporn M, Khan J, Letterio J, Leskov KS
Synthetic triterpenoids, such as 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) and its derivatives, are an extremely potent class of new anti-cancer therapeutic agents, characterized by high antitumor potency and low toxicity to normal tissues. This report is the first to investigate the effects of C-28 derivatives of CDDO on 22 pediatric solid tumor cell lines, including neuroblastoma, rhabdomyosarcoma, osteosarcoma, and Ewing's sarcoma. We determined IC50s in the range of 5 - 170 nM for inhibition of colony formation and DNA synthesis, and 110 - 630 nM for metabolic cell death and decrease in cell number, using the C-28 CDDO analogs, CDDO methyl ester (CDDO-Me), CDDO imidazolide (CDDOIm), CDDO ethyl amide (CDDO-EA), CDDO trifluoroethyl amide (CDDO-TFEA), and CDDO diethylamide (CDDO-DE). After treatment of human neuroblastoma cells with CDDO-Me, cell cycle studies show depletion of the S-phase, while apoptosis studies show conformational activation and mitochondrial translocation of Bax protein, as well as activation of caspases -3 and -8. These data demonstrate the potential utility of CDDO analogs as promising novel therapeutic agents for high-risk pediatric solid tumors.
___
Source: http://www.hubmed.org/display.cgi?uids=18277094
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc